GHRP-2
Also known as: Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102
Key Facts: GHRP-2
- Category
- Growth Hormone
- FDA Status
- Not FDA Approved
- Clinical Status
- Approved in some countries for GH deficiency diagnosis
- Administration
- Subcutaneous injection
- Typical Dose
- 100-300 mcg 2-3x daily
- Frequency
- 2-3x daily
- Evidence Level
- Human Trials
- Duration
- 8-12 weeks
What to Expect
A synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.
Mechanism of Action
GHRP-2 acts on ghrelin receptors to stimulate GH release from the pituitary. It has the strongest GH-releasing effect among GHRPs but also causes more cortisol and prolactin release than ipamorelin. Less appetite stimulation than GHRP-6.
Research Summary
Studies show it produces the highest GH release among common GHRPs. Research demonstrates reliable diagnostic use for GH deficiency testing. Animal studies show improved muscle mass and recovery.
Dosing Information
Typical Dosingⓘ
Community experience
100-300 mcg 2-3x daily
100-300 mcg per dose
2-3x daily
Less hunger increase than GHRP-6. Take on empty stomach. Often combined with a GHRH peptide.
Research Dosingⓘ
Scientific studies
Doses observed in research studies
Doses from Studies
100-300 mcg per injection
Typically 2-3x daily
Duration
8-12 weeks
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
2-3 times daily, with main dose before bed
Food Recommendation
Take on empty stomach
Why This Timing?
GHRP-2 is most effective when taken on an empty stomach. Aligns with natural GH pulsatile release patterns.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Increased appetite (less than GHRP-6)
- ●Water retention
- ●Fatigue
- ●Headache
- ●Nausea
- ●May elevate cortisol and prolactin (less than GHRP-6)
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Contraindicated with active malignancies
References
Related Peptides
Peptides commonly compared with GHRP-2 or used in similar applications.
GHRP-6
Clinical TrialsOne of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.
Growth HormoneIpamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Growth HormoneCJC-1295
Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Growth HormoneMK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Not a peptide technically, but frequently discussed alongside GH peptides due to similar effects.
Growth HormoneTesamorelin
FDAAn FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. One of the few peptides with FDA approval.
Growth HormoneSermorelin
PreclinicalA truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.
Growth HormoneWant updates on GHRP-2 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.